Prosecution Insights
Last updated: November 04, 2026
Application No. 18/867,029

METHOD FOR PREPARING CARONIC ANHYDRIDE

Non-Final OA §103§112§DP
Filed
Nov 19, 2024
Priority
May 23, 2022 — CN 202210566949.2 +1 more
Examiner
ROMERO, KRISTEN WANG
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aba Chemicals Nantong Limited
OA Round
1 (Non-Final)
70%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
37 granted / 53 resolved
+9.8% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
43 currently pending
Career history
94
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
20.7%
-19.3% vs TC avg
§102
19.8%
-20.2% vs TC avg
§112
38.9%
-1.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 53 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 3-5, 7, 9, 11, 13, 15, 19-21, 23, 25, 27, 29, 31, 33, 35, and 36 are pending. Claims 2, 6, 8, 10, 12, 14, 16-18, 22, 24, 26, 28, 30, 32, and 34 are cancelled. Status of Priority The present application is a 35 U.S.C. § 371 national stage patent application of International patent application PCT/CN2022/132714, filed on November 18, 2022. This application also claims the benefits of foreign priority to CN202210566949.2, filed on May 23, 2022. Information Disclosure Statement The instant application is accompanied with no IDS. Examiner would like to remind Applicant that “[e]ach individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b) -(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct.” See 37 C.F.R. 1.56 for more details. Specification - Abstract Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. Applicant is reminded of the proper content of an abstract of the disclosure. In chemical patent abstracts for processes, the type of reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary. Specification - Disclosure The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Objections Claims 3, 5, 7, 9, 11, 20, 23, 25, 29, and 36 are objected to because of the following informalities: To avoid 112b issues, in claims 3, 5, 7, 11, 20, 23, 25, 29, and 36: “the weight ratio” should read “a weight ratio” To avoid 112b issues, in claim 9: “the mass ratio” should read “a mass ratio” For grammatical consistency, claim 3 should read: “…s121) distilling, under atmospheric pressure at 140-145oC, the product…” For consistency, in claims 7 and 25, the degree symbol in: “… is carried out at 85-110oC…” should be superscript to read: “… is carried out at 85-110oC…” Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-5, 7, 9, 11, 13, 19-21, 23, 25, 27, 29, 31, and 36 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 1, 3-5, 7, 9, 11, 13, 19-21, 23, 25, 27, 29, 31, and 36, the phrase "preferably," “more preferably,” and/or “most preferably” render the claims indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claims 3, 5, 7, 11, 20, 23, 25, 29, and 36 recite the limitation "the weight ratio.” Claims 3 and 5 are dependent on claim 1; claims 7 and 11 are dependent on claim 5; claims 20, 23, 25, and 29 are dependent on claim 19; and claim 36 is dependent on claim 35. Claims 1, 5, 19, and 35 do not mention “a weight ratio” of the corresponding mixture recited in claims (3,5), (7, 11), (20, 23, 25, 29), and (36), respectively. Therefore, there is insufficient antecedent basis for this limitation in claims 3, 5, 7, 11, 20, 23, 25, 29, and 36. Claim 9 recites the limitation “the mass ratio of the compound of Formula (II) and the solvent.” Claim 9 is dependent on claim 7 which is dependent on claim 5, wherein claim 5 is dependent on claim 1. Claims 1, 5, and 7 do not mention “a mass ratio of the compound of Formula (II) and the solvent.” Therefore, there is insufficient antecedent basis for this limitation in claim 9. Claim 31 recites the limitation "the step iv2) comprises: removing alcohol from the reaction product obtained in the step b1) to obtain an aqueous solution of the compound of Formula (IV)…” Claim 31 is dependent on claim 29, which is dependent on claim 19, wherein claim 19 is dependent on claim 1. Claims 1, 19, and 29 do not mention a “step b1.” Therefore, there is insufficient antecedent basis for this limitation in claim 31. Note on 35 USC § 102 and § 103 Rejections In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Rejection Part 1: Claims 1, 3, and 4 are rejected under 35 U.S.C. 103 as being unpatentable over: Du et al. (Du) (CN102127040A; published July 20, 2011), All paragraph numbers cited are the paragraph numbers from the English-translated document Alfonsi et al. (Alfonsi) (Alfonsi, K. et al. Green chemistry tools to influence a medicinal chemistry and research chemistry based organization. Green Chem. 2008, 10, 31-36.), and Barich (Barich, A. Recrystallization. Chemistry LibreTexts. According to Wayback Machine, published as early as 2019. https://chem.libretexts.org/Bookshelves/Physical_and_Theoretical_Chemistry_Textbook_Maps/Supplemental_Modules_(Physical_and_Theoretical_Chemistry)/Physical_Properties_of_Matter/Solutions_and_Mixtures/Case_Studies/RECRYSTALLIZATION In view of: Fisher Scientific. Isopropyl Ether. https://www.fishersci.com/shop/products/isopropyl-ether-certified-acs-fisher-chemical/E1414 Du discloses how to prepare 6,6-dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione (i.e., caronic anhydride: PNG media_image1.png 195 238 media_image1.png Greyscale ) from 3,3-dimethyl-1,2-cyclopropanedicarboxylic acid (i.e., caronic acid: PNG media_image2.png 198 275 media_image2.png Greyscale ) in para. 0029. Those preparation steps are reproduced below: 127.5 kg (1250 mol) of acetic anhydride was first added to another 500 L reactor. Then, 79 kg (500 mol) of 3,3-dimethyl-1,2-cyclopropanedicarboxylic acid and 12.3 kg (150 mol) of anhydrous sodium acetate were added while stirring. After the substances in the reactor were mixed evenly, the temperature in the reactor was raised to 140 °C and refluxed for 1 hour. Acetic acid and acetic anhydride were distilled off under normal pressure. Then, the temperature was raised at a rate of 10 °C/h. When the temperature in the reactor reached 170 °C to 180 °C, the heating was stopped. The product was distilled off under 1000 Pa to 2000 Pa. The distilled product was recrystallized with 35 kg of methyl tert-butyl ether to obtain 47.6 kg of 6,6-dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione, with a yield of 68%. Du does not disclose isopropyl ether as the recrystallization solvent. Alfonsi is relied upon for this disclosure. Alfonsi discloses a solvent selection guide for medicinal chemistry (see Alfonsi, Fig. 1) which is reproduced below: [AltContent: rect] PNG media_image3.png 770 1255 media_image3.png Greyscale . According to Table 1 of Alfonsi, di-isopropyl ether (i.e., isopropyl ether) is considered an undesirable solvent because it is a “[v]ery powerful peroxide former.” Alfonsi suggests that a good solvent alternative to use is MTBE (see Alfonsi, Table 2). Therefore, one of ordinary skill in the art would have found it prima facie obvious before the effective filing date of the claimed invention to modify Du’s method of preparing caronic anhydride by replacing the MTBE used to recrystallize caronic anhydride with isopropyl ether. A POSITA would have had a reasonable expectation that isopropyl ether would successfully recrystallize caronic anhydride and provide results similar to those obtained using MTBE because Alfonsi identifies MTBE and isopropyl ether as interchangeable alternative ether solvents for performing the same general solvent function. Although Alfonsi expresses a safety preference for MTBE, this preference does not establish that isopropyl ether is chemically unsuitable or inoperative as a solvent. Rather, Alfonsi’s identification of tert-butyl MTBE as an alternative to isopropyl ether suggests that the two solvents were recognized as functionally related ether solvents capable of serving the same general solvent function. Accordingly, a POSITA would have expected isopropyl ether to also successfully recrystallize the caronic anhydride prepared using Du’s method. In fact, this is consistent with what is reported by Du and by the instant specification. Du reports obtaining caronic anhydride in a 68% yield when MTBE was used as the recrystallization solvent (see para. 0029, last sentence). The instant specification reports a similar product yield of 65.3% (see instant Table 5, last row). Thus, the use of isopropyl ether (as reported in the instant specification), does not provide an unexpected outcome relative to Du’s use of MTBE. Instead, the reported results are consistent with the similar performance that would have been expected from the known alternative ether solvents. See MPEP 2144.06(II). As such, instant claims 1 and 3 are rendered obvious. Moreover, even though Du does not disclose the exact recrystallization steps, the procedure for this method of compound purification is routine and known in the art. According to Barich, to recrystallize a compound: the crude compound is first dissolved in boiling solvent, then the solution is cooled slowly in open air first and then cooled in an ice bath (see “Procedure” section in Barich). Therefore, when recrystallizing caronic anhydride in isopropyl ether as the solvent, it is obvious to first dissolve the crude caronic anhydride in isopropyl ether at a high temperature between 50-70oC (i.e., a temperature range that encompasses the boiling point of isopropyl ether: 68oC; see Fisher Scientific) and subsequently cool the clear solution to a low temperature. As such, instant claim 4 is rendered obvious. Rejection Part 2: Claims 1, 3-5, 7, 9, 11, 13, and 15 are rejected under 35 U.S.C. 103 as being unpatentable over: The references listed in Rejection Part 1 and Qin et al. (Qin) (CN104163759A; published November 26, 2014.) All paragraph numbers cited are the paragraph numbers from the English-translated document; All paragraph numbers within figures correspond to the paragraph numbers of the original Chinese document. in view of: Fernanda, How can TEMPO be used to oxidize alcohols in a two-phase solvent system? Chemical Trading Guide 2021, https://www.guidechem.com/question/how-can-tempo-be-used-to-oxidi-id148063.html The method for preparing caronic anhydride from caronic acid, as disclosed in instant claims 1, 3, and 4, was rendered obvious over the teachings disclosed in Du, Alfonsi, and Barich. See “Rejection Part 1” above for details. Du does not disclose a method of preparing caronic acid comprising a step involving a compound of instant formula I reacting with a compound of instant formula II. Qin is relied upon for this disclosure. Synthesizing a compound of instant formula III Qin discloses how to synthesize a compound of instant formula III (see para. 0059): PNG media_image4.png 311 1095 media_image4.png Greyscale Add intermediate Ia (54g), copper catalyst (0.5g, a 1:1 complex of cuprous trifluoromethanesulfonate and benzonitrile) to the reaction flask, and 200ml of dichloroethane. Heat to 60-65℃. Add 48 g of ethyl diazonium acetate II dissolved in 100 ml of dichloroethane dropwise to the system, and continue adding dropwise while maintaining an internal temperature of 60-85℃. Continue stirring for 30 minutes after the dripping is complete. Reduced pressure distillation was performed, and the fraction collected at 117-120℃/1kPa was used to obtain 60g of intermediate IIIa. Synthesizing a compound of instant formula IV Qin discloses that hydrolyzing a compound of instant formula III would yield a compound of instant formula IV by (see para. 0131-0132): PNG media_image5.png 216 942 media_image5.png Greyscale Intermediate III (8.3 g) was mixed with water (9 ml). Stir and heat to 50°C, then add dropwise 28wt% sodium hydroxide aqueous solution (24.2g). Keep warm at 50℃ for 2 hours. An aqueous solution of intermediate IV (3-hydroxymethyl-2,2-dimethylcyclopropylformic acid) was obtained. It can be used directly in the next reaction. Take 10g of the reaction solution, acidify to pH 1, keep warm for 2 hours, adjust the pH to 9, extract with ethyl acetate, and dry to obtain the cis-lactone product. The pH of the remaining aqueous solution was adjusted to 1, extracted with ethyl acetate, and dried and concentrated to obtain trans compound IV: PNG media_image6.png 285 599 media_image6.png Greyscale . Synthesizing caronic acid Qin discloses that oxidizing a compound of instant formula IV using a TEMPO oxidation system would yield caronic acid (see para. 0194-0195): PNG media_image7.png 242 1132 media_image7.png Greyscale Add 50% sulfuric acid to the aqueous solution of intermediate IV, which has been cooled to 5oC, to adjust the pH to 8-10, then add 5 mL of acetonitrile and 0.3 g of potassium bromide. Add 0.1 g of tetramethylpiperidine oxide [i.e., TEMPO] and dropwise add a 12% sodium hypochlorite aqueous solution (chlorine content 10%, approximately 20 g). Stir for 20 minutes. Adjust the pH to 4-7 and add 16g of a 25% sodium chlorite aqueous solution. Stir for 2 hours after dripping. The reaction system was poured into a sodium sulfite aqueous solution at 0°C, the pH was adjusted to 1 with hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain 2g of caronic acid. Note: Even though Qin does not explicitly disclose sodium bicarbonate being added to the reaction mixture as part of the TEMPO oxidation system, it is known in the prior art (see Fernanda) that sodium bicarbonate is necessary in TEMPO oxidation reactions to help maintain the pH of the system at 8.6-9.5. Therefore, “bicarbonate” being a required component of the TEMPO oxidation system as recited in instant claim 5 is not novel and considered obvious. Therefore, a person of ordinary skill in the art would have found it prima facie obvious before the effective filing date of the claimed invention to prepare caronic acid according to the method disclosed by Qin (see sections “1. Synthesizing a compound of instant formula III,” “2. Synthesizing a compound of instant formula IV,” and “3. Synthesizing caronic acid” above) and using the resulting caronic acid in the method of Du (as modified by Alfonsi and Barich; discussed in Rejection Part 1) to prepare caronic anhydride. A POSITA would have been motivated to make this combination because Qin explicitly states that the new synthetic method of caronic acid has the advantage of mild conditions, high production safety, and easy industrialized production (see Qin, abstract). Furthermore, a POSITA would also have had a reasonable expectation of success in combining the teachings of Qin and Du (as modified by Alfonsi and Barich) because the caronic acid prepared according to Qin is the same chemical compound employed in Du’s cyclization reaction. Du’s conversion of caronic acid to caronic anhydride does not depend upon the particular synthetic route of caronic acid. Accordingly, a POSITA would have expected that the caronic acid prepared by Qin can also undergo Du’s cyclization and recrystallization procedures successfully, thereby producing caronic anhydride. As such, instant claims 1, 3-5, 7, 9, 11, 13, and 15 are rendered obvious. Rejection Part 3: Claims 1, 3-5, 7, 9, 11, 13, 15, 19-21, 23, 25, 27, 29, 31, 33, 35, and 36 are rejected under 35 U.S.C. 103 as being unpatentable over: The references listed in Rejection Part 1 and Rejection Part 2 and Zhao (CN103012132A; published April 3, 2013.) All paragraph numbers cited are the paragraph numbers from the English-translated document Schörghuber et al. (Schörghuber) (Schörghuber, J. et al. Highly Selective Stable Isotope Labeling of Histidine Residues by Using a Novel Precursor in E. coli-Based Overexpression Systems. ChemBioChem 2017, 18, 1487-1491.) in view of Shim et al. (Shim) (US3897478A; published July 29, 1975). The method for preparing caronic anhydride from caronic acid, as disclosed in instant claims 1, 3, and 4, was rendered obvious over the teachings disclosed in Du, Alfonsi, and Barich. See “Rejection Part 1” above for details. Du does not disclose a method of preparing caronic acid comprising: a step involving a compound of instant formula I reacting with a compound of instant formula II wherein a compound of instant formula I is synthesized from a starting material containing isopentenol, acetic anhydride, and carbonate and a compound of instant formula II is synthesized from a starting material containing glycine ethyl ester hydrochloride, sodium nitrite, a catalyst, and a solvent. Zhao, Schörghuber, and Qin are relied upon for this disclosure. Their teachings are discussed below. Zhao teaches a method of preparing the compound of instant formula (I’) according to the following (see para. 0029): PNG media_image8.png 189 784 media_image8.png Greyscale 1020 kg of acetic anhydride was pumped into the reactor and 41 kg of sodium acetate was added. After heating to 100oC, 1634 kg of pentadienol was added dropwise at 100-110oC. After the addition was completed in about 4 hours, the reaction was kept at this temperature for 2 hours. The reaction endpoint was when the pentadienol content in the solution was less than 0.5%. Schörghuber teaches a method of preparing the compound of instant formula (II’) according to the following (see scheme 2 and pg. 1488, left col., the 4th-6th line after “scheme 1” which begins with “This compound 2 was first treated with NaNO2…”): PNG media_image9.png 354 844 media_image9.png Greyscale . Note: According to Shim, H2SO4 is the acid catalyst (see col. 2, lines 3-10). Qin discloses a method of synthesizing the compound of instant formula (III’), the compound of instant formula (IV), and caronic acid. See Rejection Part 2 for details. Therefore, a person of ordinary skill in the art would have found it prima facie obvious before the effective filing date of the claimed invention to prepare caronic acid according to the method disclosed by Qin (see sections “1. Synthesizing a compound of instant formula III,” “2. Synthesizing a compound of instant formula IV,” and “3. Synthesizing caronic acid” of Rejection Part 2) and using the resulting caronic acid in the method of Du (as modified by Alfonsi and Barich; discussed in Rejection Part 1) to prepare caronic anhydride. A POSITA would have been motivated to make this combination because Qin explicitly states that the new synthetic method of caronic acid has the advantage of mild conditions, high production safety, and easy industrialized production (see Qin, abstract). Furthermore, a POSITA would also have had a reasonable expectation of success in combining the teachings of Qin and Du (as modified by Alfonsi and Barich) because the caronic acid prepared according to Qin is the same chemical compound employed in Du’s cyclization reaction. Du’s conversion of caronic acid to caronic anhydride does not depend upon the particular synthetic route of caronic acid. Accordingly, a POSITA would have expected that the caronic acid prepared by Qin can also undergo Du’s cyclization and recrystallization procedures successfully, thereby producing caronic anhydride. Furthermore, a POSITA would have found it obvious to prepare the compound of instant formula I’ according to Zhao and the compound of instant formula II’ according to Schörghuber and proceed with the reaction according to Qin and Du (as modified by Alfonsi and Barich) to ultimately form caronic anhydride. The fact that the compound of instant formula I’ and formula II’ can be prepared by methods disclosed in separate references (i.e., Zhao and Schörghuber, respectively) does not render the claimed overall process nonobvious. A POSITA would have understood that a required intermediate may be prepared by any known suitable method and that the intermediate’s subsequent reactivity depends on its chemical identity, not on the particular route used to prepare it. Selecting known literature methods to prepare the required starting materials and then using those materials in their already-disclosed downstream reactions would, therefore, have involved no more than connecting known synthetic steps according to their established purposes. A POSITA would also have had a reasonable expectation of success by combining the teachings of Zhao, Schörghuber, Qin, and Du (as modified by Alfonsi and Barich) because the product of each known step is the starting material required by the next known step. The proposed combination does not change the identity or expected function of any intermediate, produce a different final product, or require any intermediate to undergo a previously unknown reaction. Instead, the combination predictably proceeds from Formula I’ and Formula II’ to Formula III’, Formula IV, caronic acid, and ultimately caronic anhydride. In the absence of evidence that the selected preparative routes produce a critical or unexpected effect, assembling these known steps into the claimed sequence would have been obvious to one of ordinary skill in the art. As such, instant claims 1, 3-5, 7, 9, 11, 13, 15, 19-21, 23, 25, 27, 29, 31, 33, 35, and 36 are rendered obvious. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3-5, 7, 9, 11, 13, 15, 19-21, 23, 25, 27, 29, 31, 33, 35, and 36 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over: claims 1-5, 7-9, 11, 12, 15-19, 21, 25, 29, 33, and 34 of U.S. Patent Application No. 18/867,037 in view of: the references cited in Rejection Part 1, Rejection Part 2, and Rejection Part 3 of the “Claim Rejections - 35 USC § 103” section above. Although the claims at issue are not identical, they are not patentably distinct from each other because there is significant overlap between the instant claims and the claims from the co-pending application. Claims 1-5, 7-9, 11, 12, 15-19, 21, 25, 29, 33, and 34 of the co-pending application recites a method of preparing caronic acid. This method of preparing caronic acid, as described by the claims of the co-pending application, is also recited in instant claims 5, 7, 9, 11, 13, 15, 19-21, 23, 25, 29, and 33. Therefore, one of ordinary skill in the art would have found it obvious to claim a method for preparing caronic anhydride from caronic acid (which is a method rendered obvious in view of the discussion and references cited in Rejection Part 1, Rejection Part 2, and Rejection Part 3 of the “Claim Rejections - 35 USC § 103” section above), wherein the caronic acid is prepared using the method recited in the claims of the co-pending application. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTEN ROMERO whose telephone number is (571)272-6478. The examiner can normally be reached M-F 9:30 AM - 6:00 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY H. MURRAY can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTEN W ROMERO/Examiner, Art Unit 1624 /JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 19, 2024
Application Filed
Sep 28, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780826
POTENT AND SELECTIVE INHIBITORS OF HER2
3y 8m to grant Granted Nov 03, 2026
Patent 12767650
CRYSTAL FORM OF ENTRECTINIB AND PREPARATION METHOD THEREFOR
3y 2m to grant Granted Oct 20, 2026
Patent 12747229
PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF
3y 6m to grant Granted Sep 29, 2026
Patent 12747217
PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES
3y 4m to grant Granted Sep 29, 2026
Patent 12740993
CANNABINOIDS AND USES THEREOF FOR TREATMENT OF ESTROGEN RECEPTOR RELATED DISEASES
3y 2m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
70%
Grant Probability
99%
With Interview (+30.8%)
3y 2m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 53 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month